{"organizations": [], "uuid": "3aacf752a87a2cebe1a2fffbf770c87ce9509407", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-shionogi-announces-fda-nda-ema-maa/brief-shionogi-announces-fda-nda-ema-maa-acceptances-for-lusutrombopag-idUSASB0C7GL", "country": "US", "domain_rank": 408, "title": "BRIEF-Shionogi Announces FDA NDA, EMA MAA Acceptances For Lusutrombopag", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T18:37:00.000+02:00", "replies_count": 0, "uuid": "3aacf752a87a2cebe1a2fffbf770c87ce9509407"}, "author": "", "url": "https://www.reuters.com/article/brief-shionogi-announces-fda-nda-ema-maa/brief-shionogi-announces-fda-nda-ema-maa-acceptances-for-lusutrombopag-idUSASB0C7GL", "ord_in_thread": 0, "title": "BRIEF-Shionogi Announces FDA NDA, EMA MAA Acceptances For Lusutrombopag", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda nda", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "lusutrombopag", "sentiment": "none"}, {"name": "lusutrombopag reuters staff", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters) - shionogi & co ltd", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "shionogi & co ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 26, 2018 / 4:37 PM / Updated 35 minutes ago BRIEF-Shionogi Announces FDA NDA, EMA MAA Acceptances For Lusutrombopag Reuters Staff 1 Min Read Feb 26 (Reuters) - Shionogi & Co Ltd: * SHIONOGI ANNOUNCES FDA NEW DRUG APPLICATION (NDA) AND EMA MARKETING AUTHORIZATION APPLICATION (MAA) ACCEPTANCES FOR LUSUTROMBOPAG (S-888711) * SHIONOGI & CO LTD - PRESCRIPTION DRUG USER FEE ACT DATE FOR AN FDA DECISION FOR LUSUTROMBOPAG IS AUGUST 26, 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-26T18:37:00.000+02:00", "crawled": "2018-02-26T19:13:59.011+02:00", "highlightTitle": ""}